1. Cardiovascular Implants

2. The total cost (direct and indirect) for CVD in the United States was almost 450 billion USD in 2008 CVD is also the leading cause of death worldwide and is projected to remain so for decades

9. HEART VALVE PROSTHESIS Heart valves open and close over 40 million times a year and they can accumulate damage sufficient to require replacement in many individuals. More than 80,000 replacement valves are implanted each year in the United States. There are many types of heart valve prostheses and they are fabricated from carbons, metals, elastomers, plastics, fabrics and animal or human tissues

12. HEART VALVE PROSTHESIS Generally, almost as soon as the valve is implanted, cardiac function is restored to near normal levels and the patient shows rapid improvement. In spite of the overall success seen with replacement heart valves, there are problems that may differ with different types of valves; they include induction of blood clots, degeneration of tissue, mechanical failure, and infection.

14. Coronary heart disease

16. Atherosclerosis A chronic, progressive, multifocal disease of the vessel wall intima Affects the large elastic arteries and large and medium-sized muscular arteries At points of branches, sharp curvatures Mature atherosclerotic plaques consist of: – A central core of lipid and cholesterol crystals and cells such as macrophages and smooth muscle cells along with necrotic debris, proteins and degenerating blood elements Complications of atherosclerosis: – Obstruction of a vascular – Disruption of a plaque followed by thrombus formation – Destruction of the underlying vascular wall

23. Atrial Septal Defect closure that will close the hole in the heart wall.

25. Vascular grafts Synthetic grafts: – Perform well in large-diameter, high-flow, low-resistance locations such as the aorta – Synthetic small-diameter vascular grafts (<6 to 8 mm in diameter) generally perform less well with 5-year patency less than 50% Natural grafts: – The iliac and proximal femoral arteries, with grafts used for aortofemoral bypass having 5- to 10-year patency rates of 90% – The saphenous vein (superficial vein in the leg) is typically removed surgically and moved to the site needed to bypass blockages in the coronary circulation (for coronary artery bypass grafting)

26. Vascular graft research Resolving one problem may introduce another Eliminating the underlying cause of the chronic foreign body response by using resorbable materials Introduction new elastomers Implanting dense, tissue-engineered tubes of smooth muscle cells Endothelium detachment in vein grafts Surface modifications for: – Prevent coagulation, prevent platelet adhesion/aggregation, promote fibrinolysis, inhibit smooth muscle cell adhesion/proliferation, and promote endothelial cell adhesion and proliferation.

29. Example: The 5.0-mm ID, 7-cm-long graft implantation in the common carotid artery advantages over polyester and Teflon: elasticity and ease of handling

30. Major complications of vascular grafts Failure of small-diameter vascular prostheses due to: – Occlusion by thrombus formation – Fibrous hyperplasia (excessive cell reproduction) Thrombosis Thromboembolism Infection Pseudoaneurysm (an extravascular hematoma that communicates with the intravascular space) Intimal hyperplasia, and structural degeneration

34. Stent implantation often follows balloon angioplasty

35. Characteristics of an ideal stent ? Ability to hold on the balloon catheter supported by a guide wire Good expandability ratio – After insertion at the target area and the balloon is inflated, the stent should undergo sufficient expansion and conform to the vessel wall Sufficient radial strength – Implanted, the stent should be able to overcome the forces imposed by the atherosclerotic arterial wall and should not collapse Sufficient flexibility – It should be flexible enough to travel through even the smaller diameter atherosclerotic arteries Adequate radiopacity/magnetic resonance imaging (MRI) compatibility – To assist clinicians in assessing the in-vivo location of the stent Thromboresistivity – The material should be blood compatible and not encourage platelet adhesion and deposition Drug delivery capacity – Essential requirements for stents of the modern era to prevent restenosis

40. Future Stents Material used for making stents: – Mechanical properties – Suitable surface characteristics – Excellent haemo-compatibility – Good biocompatibility – Drug delivery capacity Drug eluting stent: future of coronary stents: FDA approved Percutaneous transluminal coronary angioplasty cannot be performed without damaging blood vessels and eliciting restenosis – Drug elution at the target site is a clear solution to this problem. Developing new polymer materials – Hemocompatibility, hydrophobicity, anti-inflammatory, conformability to the stent size, sterilizability and biodegradability

42. Intravascular filter Venous thromboembolic disease: Significant cause of mortality due to the complication of pulmonary embolism Formation: – Thrombus detached from the wall of the vein – Travel through the inferior vena cava to the right side of the heart – Embolus in one of the large branches of the pulmonary Artery Therapy: – Anticoagulation drug such as warfarin and/or heparin – High risk of bleeding

43. Vena caval filters: (A): A, The stainless steel Greenfield filter; B, the modified-hook titanium Greenfield filter; C, the bird’s-nest filter; D, the Simon nitinol filter; E, the Vena Tech filter (alloy of cobalt, chromium). (B): Photo of vena caval filter at autopsy demonstrating some thrombus at the filter site

44. RAPEASE® Permanent Vena Cava Filter OPTEASE® Retrievable Vena Cava Filter

51. Pulmonary Valved Conduit Contegra® – Natural alternative for reconstruction or replacement of the natural right ventricular outflow tract (congenital heart valve defects) – An animal jugular vein that contains a valve with three leaflets (to correct or reconstruct the path that blood takes to travel from the heart to the lungs). – Similar to a human heart valve.

54. Pacemaker